阿托伐他汀联合肠溶阿司匹林对颈动脉粥样硬化患者斑块稳定性及脑血管事件的影响

目的 观察标准剂量阿托伐他汀联合肠溶阿司匹林对颈动脉粥样硬化患者斑块稳定性及脑血管事件的影响. 方法 将67例颈动脉粥样硬化患者随机分成2组,治疗组34例,对照组33例,治疗组口服阿托伐他汀(10 mg/d)和肠溶阿司匹林(100 mg/d),对照组仅口服肠溶阿司匹林(100 mg/d).观察2组患者在治疗6月、12月后颈动脉粥样硬化斑块缩小程度及脑血管事件的发生率.结果 治疗6月后2组颈动脉斑块大小及脑血管事件的发生率变化无统计学差异(P＞0.05),但治疗组稳定性斑块数目增加,与治疗前比较差异有统计学意义(P＜0.01).治疗12月后2组斑块大小、稳定性斑块数目及脑血管事件的发生率与治疗前比较均有统计学差异(P＜0.01),2组间也存在显著性差异(P＜0.05).结论 阿托伐他汀联合阿司匹林治疗可通过调节颈动脉粥样硬化患者炎性细胞因子,抑制血小板活化,缩小或稳定颈动脉粥样硬化斑块,长时间服用可降低脑血管事件的发生率.

Effect of atorvastatin combined with enteric-coated aspirin on plaque stability and cerebrovascular events in patients with carotid atherosclerosis

Objective To observe the effect of atorvastatin combined with enteric-coated aspirin on plaque stability and cerebrovascular events in patients with carotid atherosclerosis.Methods Sixty-seven patients with carotid atherosclerosis were randomly divided into two groups,treatment group(n=34) and control group(n=33).The treatment group was treated with atorvastatin 10 mg/d and enteric-coated aspirin 100 mg/d,whereas the control group was treated with enteric-coated aspirin 100 mg/d for 12 months.Plaque size and the incidence of cerebrovascular events were observed.Results After 6 months,there was no singnificant changes in plaque size and the incidence of cerebrovascular events between the two groups(P>0.05),but the plaque stability was inctreased significantly after treatment in treatment group(P<0.01).After 12 months,there was significant difference in plaque size,plaque stability and the incidence of cerebrovascular events between two groups(P<0.05).Conclusions Atorvastatin combined with enteric-coated aspirin can be used for adjustment to inflammatory cytokines in patients with carotid atherosclerosis to inhibit platelet activation and reduce or stabilize carotid atherosclerotic plaques.Long-time taking atorvastatin and enteric-coated aspirin can reduce the occurrence of cerebrovascular events.